|
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
|
Written by: J. Smith |
Hits: 1039
|
|
Exploring CGM Data
|
Written by: J. Smith |
Hits: 976
|
|
Dexcom and Oura: A Strategic Partnership to Revolutionize Metabolic Health Tracking
|
Written by: J. Smith |
Hits: 1224
|
|
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
|
Written by: J. Smith |
Hits: 959
|
|
Novo Nordisk Advances Semaglutide in MASH Treatment Following ESSENCE Trial Success
|
Written by: J. Smith |
Hits: 1161
|
|
Wegovy’s Lowest Dose Now Available in the U.S.
|
Written by: J. Smith |
Hits: 946
|
|
Dexcom Submits 15-Day G7 CGM to FDA for Approval
|
Written by: J. Smith |
Hits: 2268
|
|
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 1093
|
|
Novo Nordisk Unveils Glucose-Sensitive Insulin to Reduce Hypoglycemia Risk
|
Written by: J. Smith |
Hits: 1828
|
|
FDA Reconsiders Tirzepatide Shortage Status
|
Written by: J. Smith |
Hits: 1288
|
